Endothelin analogues with alpha-amine substitution at residue 20
CA 2072390 A1 · Owner: Hunt, John T. · Inventors: Stein, Philip D.; Hunt, John T.; Natarajan, Sesha I.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
HA575, Abstract, ENDOTHELIN ANALOGUES WITH ALPHA- AMINE SUBSTITUTION AT RESIDUE 20, Endothelin receptor antagonism is exhibited by novel compounds of the formula, wherein: ;, R9 is alkyl, alkenyl, alkynyl, alkoxy cycloalkyl, cycloalkylalkyl, cycloalkenyl cycloalkenylalkyl, aryl, or aralkyl;, R10 is alkyl alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl cycloalkenyl, or, cycloalkenylalkyl;, or R9 and R10 together are an alkylene chain of three to five carbons (e.g. such that A20 is prolyl), optionally substituted with one or two alkyl, alkoxy, aryl, aralkyl, cycloalkyl or, hydroxy groups;, and the remaining symbols are as defined in the specification.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 25, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.